Clinical trial
Zemaira (Alpha-1-Proteinase Inhibitor) Therapy in HIV-1 Disease
NCT01370018 is registered in ClinicalTrials.gov with Institute for Human Genetics and Biochemistry as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Zemaira (Alpha-1-Proteinase Inhibitor) Therapy in HIV-1 Disease
- Lead sponsor
- Institute for Human Genetics and Biochemistry
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- December 31, 2006
- Completion date
- February 28, 2007
- Enrollment
- 4 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hiv disease